HUE032771T2 - Deuterizált ivacaftor-származékok - Google Patents
Deuterizált ivacaftor-származékok Download PDFInfo
- Publication number
- HUE032771T2 HUE032771T2 HUE12725197A HUE12725197A HUE032771T2 HU E032771 T2 HUE032771 T2 HU E032771T2 HU E12725197 A HUE12725197 A HU E12725197A HU E12725197 A HUE12725197 A HU E12725197A HU E032771 T2 HUE032771 T2 HU E032771T2
- Authority
- HU
- Hungary
- Prior art keywords
- compound
- formula
- deuterium
- pharmaceutically acceptable
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Saccharide Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (10)
- Szabadalmi igénypontok L Egy (|) képletü vegyidet(I) képiéi vagy gyógyászatilag elfogadható sója, ahol X\ Xg X\ X4, X5, X* és X7 mindegyikének jelentése» egymástól függetlenül, hidrogén vagy deutérium; Y\ \ ' <N V5 jelentést ( TE; \ \ Y" e,s V" nrvjcgjfoéneh jelenteje egymástól függetlenül, € IE nig> t l>n ahol ,v izotop-feldúsnlósi faktor minien egyef felilafotett denfoditiifomra legalább 3500; és ahol Mimely, et ökati természetes Izofop^eldíbtdulási gyakoriságával^» je- 1¾ azzal a feltétellel, hogy ez CD képlet« vegyidet nem a (100) vegyület;(JÖO) vegyidet : λ/ t igénypont *«awm végsőiét ahol V, X\ X' é\ V kraue aeetvs
- 5. Λ l. igénypont szériád vegyük!, ahol \ \ \ - es V' jelentése azonos. 4 A 2 vag\ 3 igénypont ^enno vus hkt, ahol X'N ^ \ " jeka áe eeonos \ Az előző igénypontok hántoljíkc afetmtj \eg>0kt, ok . Vjek-nese Jetiiét mm
- 6, Az efbzb igénypontok bánremke szerinti vegyüld. ahol Vk V' <6 Y* jelentése CD»
- 7. Az I ~4. igénypontok bármelyike szerinti vegyilitj âKôl jelentése hidrogén tíAz M, igénypontok bármelyike szerinti vegyüld, ahol Yk Y' és Y* jelentése Oh, H .&% 1. igénypont sz emití titt ,iho » /o j fokk mkmt ao ak t * hó tüntetett deutémnnatomra legalább éööü.
- 10. Az l. igénypont szerinti. vtgy$|gfjí |^|.fp|^pt^felàôsàÎÂiÉÂÂitàéh''é^<S .tii* tüntetett deoíériutmuomra legalább 6333,3. 11. 9. Az 1, igénypont szerinti vegyidet ahol az izotop-íddústdfo? faktor minden egyes feltüntetett deoíériomatomrs legalább 6466,7,
- 12. Az 1. igénypont yagy a foil, Iglpyfbniblv MÉPeiylke szerinti vegyidet, ahofdz (í) képlett! vegyidet az alábbi táblázatban megadoh vegyidetek bármelyike:vagy estek gyógyászatdag elfogadható sója.
- 13. AI: 1. igénypont vagy a 7-1 !. igénypontok bármelyike szerinti vegyüld, öltol az (M képlett! vegyidet az alábbi táblázatban megadott vegyüle!vagy gyógyászaiban ei.fogad.hal6 sója. Id. Gyógyászati készítmény, Mély iaddnía#egy vegyülhet vagy annak gyégyászatilag elfogadható sóiái, valamim agy gyôgyâszaîda§ elii>» fgfeaió hordozót, iá Az 1*13. igénypontok bármelyike szerint? vegyület vagy a 14, igénypont szerinti ke* pltótóiy ciszíás ílbrózls kezelésére történd alkalmaim.
- 16. Az 1*13, igénypontok bármelyike szerimi vegyidet vagy a 14. igénypont szerinti készítmény alkalmazása chiiás íibrózh keaæîÉ^:^lgéjiip%p^ elÄÄfe
- 17. Az 1"13. iginyplitokHifiiét vagy a 14. igéstypont szerinti ké-szíboény krónikus obstruktiv riidé&eíepég (CÖFÖ) kezelésére történd alkalmazásom.
- 18. Az M3, igénypontok bármelyike szerimi vegyülni vagy a 14, igénypont szerinti késs nme ny alkalmazása krónikus öhsMtöv tudÉbOtógSég kézéíitó^^:§^ szer előállítására.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487497P | 2011-05-18 | 2011-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE032771T2 true HUE032771T2 (hu) | 2017-10-30 |
Family
ID=46201810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12725197A HUE032771T2 (hu) | 2011-05-18 | 2012-05-17 | Deuterizált ivacaftor-származékok |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP3235812B1 (hu) |
| JP (2) | JP6063455B2 (hu) |
| AU (5) | AU2012255711B2 (hu) |
| BR (1) | BR112013029240B1 (hu) |
| CA (1) | CA2834574C (hu) |
| CY (2) | CY1119090T1 (hu) |
| DK (2) | DK3235812T3 (hu) |
| EA (1) | EA028378B1 (hu) |
| ES (2) | ES2758028T3 (hu) |
| HK (1) | HK1244183A1 (hu) |
| HR (2) | HRP20170754T1 (hu) |
| HU (1) | HUE032771T2 (hu) |
| LT (1) | LT2709986T (hu) |
| ME (2) | ME03652B (hu) |
| MX (1) | MX349159B (hu) |
| PL (2) | PL3235812T3 (hu) |
| PT (2) | PT3235812T (hu) |
| RS (2) | RS56096B1 (hu) |
| SI (2) | SI3235812T1 (hu) |
| WO (1) | WO2012158885A1 (hu) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0620960A2 (pt) | 2005-12-28 | 2011-11-29 | Vertex Pharmaceuticals Incorporated | formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-didro-4- oxiquinolina-3- carboxamida |
| CA2834574C (en) * | 2011-05-18 | 2019-09-17 | Concert Pharmaceuticals Inc. | Deuterated derivatives of ivacaftor |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| WO2013151758A2 (en) | 2012-04-06 | 2013-10-10 | The Uab Research Foundation | Methods for increasing cftr activity |
| JP6146990B2 (ja) * | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| WO2014078842A1 (en) * | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
| JP6896619B2 (ja) | 2014-10-06 | 2021-06-30 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーター |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| AU2016243171B2 (en) | 2015-03-31 | 2020-10-08 | Concert Pharmaceuticals, Inc. | Deuterated VX-661 |
| AU2016297886B2 (en) | 2015-07-24 | 2020-12-10 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing CFTR activity |
| CA2998911C (en) * | 2015-09-21 | 2023-05-23 | Vertex Pharmaceuticals (Europe) Limited | Administration of deuterated cftr potentiators |
| AU2016327603B2 (en) * | 2015-09-25 | 2021-04-22 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR potentiators |
| US10662207B2 (en) * | 2016-04-07 | 2020-05-26 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating CFTR |
| ES2954658T3 (es) | 2016-06-21 | 2023-11-23 | Proteostasis Therapeutics Inc | Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR |
| JP2017105824A (ja) * | 2017-02-10 | 2017-06-15 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| US11708331B2 (en) * | 2017-12-01 | 2023-07-25 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| JP6654223B2 (ja) * | 2018-08-13 | 2020-02-26 | バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド | 重水素化されたｃｆｔｒ増強物質 |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| KR20220064366A (ko) | 2019-08-14 | 2022-05-18 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 조절제의 결정질 형태 |
| TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| US20220313698A1 (en) | 2019-08-14 | 2022-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| LV15575A (lv) | 2019-12-20 | 2021-06-20 | Latvijas Organiskās Sintēzes Institūts | Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| IL300413A (en) | 2020-08-13 | 2023-04-01 | Vertex Pharma | Crystal forms of CFTR modulators |
| EP3970718A1 (en) | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators |
| EP4225748A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076620A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230373974A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230416275A1 (en) | 2020-10-07 | 2023-12-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CR20230197A (es) | 2020-10-07 | 2023-07-06 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| CA3197857A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225737A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230382924A1 (en) | 2020-10-07 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL301757A (en) | 2020-10-07 | 2023-05-01 | Vertex Pharma | Cystic fibrosis transmembrane regulator conductance modulators |
| WO2022125826A1 (en) | 2020-12-10 | 2022-06-16 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
| WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2023196429A1 (en) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040068613A (ko) * | 1994-03-25 | 2004-07-31 | 이소테크니카 인코포레이티드 | 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물 |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| NZ528689A (en) | 2001-05-03 | 2005-03-24 | F | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| PT2489659T (pt) * | 2004-06-24 | 2018-03-07 | Vertex Pharma | Moduladores de transportadores de cassete de ligação a atp |
| CA2581169A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| CA2635214A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
| BRPI0620960A2 (pt) | 2005-12-28 | 2011-11-29 | Vertex Pharmaceuticals Incorporated | formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-didro-4- oxiquinolina-3- carboxamida |
| ATE534383T1 (de) | 2006-05-12 | 2011-12-15 | Vertex Pharma | Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid |
| EP2727915B1 (en) * | 2007-09-13 | 2016-04-13 | Concert Pharmaceuticals Inc. | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof |
| NO2328618T3 (hu) | 2008-08-13 | 2018-04-28 | ||
| UA104005C2 (ru) * | 2008-09-03 | 2013-12-25 | Тева Фармасьютикл Индастриз, Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
| CA2834574C (en) * | 2011-05-18 | 2019-09-17 | Concert Pharmaceuticals Inc. | Deuterated derivatives of ivacaftor |
-
2012
- 2012-05-17 CA CA2834574A patent/CA2834574C/en active Active
- 2012-05-17 ME MEP-2019-325A patent/ME03652B/me unknown
- 2012-05-17 ME MEP-2017-112A patent/ME02749B/me unknown
- 2012-05-17 PL PL17160386T patent/PL3235812T3/pl unknown
- 2012-05-17 ES ES17160386T patent/ES2758028T3/es active Active
- 2012-05-17 EP EP17160386.3A patent/EP3235812B1/en active Active
- 2012-05-17 AU AU2012255711A patent/AU2012255711B2/en active Active
- 2012-05-17 BR BR112013029240-7A patent/BR112013029240B1/pt active IP Right Grant
- 2012-05-17 RS RS20170601A patent/RS56096B1/sr unknown
- 2012-05-17 HU HUE12725197A patent/HUE032771T2/hu unknown
- 2012-05-17 LT LTEP12725197.3T patent/LT2709986T/lt unknown
- 2012-05-17 EA EA201391615A patent/EA028378B1/ru unknown
- 2012-05-17 DK DK17160386T patent/DK3235812T3/da active
- 2012-05-17 SI SI201231694T patent/SI3235812T1/sl unknown
- 2012-05-17 ES ES12725197.3T patent/ES2628465T3/es active Active
- 2012-05-17 WO PCT/US2012/038297 patent/WO2012158885A1/en active Application Filing
- 2012-05-17 DK DK12725197.3T patent/DK2709986T3/en active
- 2012-05-17 PT PT171603863T patent/PT3235812T/pt unknown
- 2012-05-17 MX MX2013013450A patent/MX349159B/es active IP Right Grant
- 2012-05-17 JP JP2014511524A patent/JP6063455B2/ja active Active
- 2012-05-17 PT PT127251973T patent/PT2709986T/pt unknown
- 2012-05-17 EP EP12725197.3A patent/EP2709986B1/en active Active
- 2012-05-17 PL PL12725197T patent/PL2709986T3/pl unknown
- 2012-05-17 RS RS20191494A patent/RS59744B1/sr unknown
- 2012-05-17 SI SI201230988A patent/SI2709986T1/sl unknown
-
2016
- 2016-12-16 JP JP2016243941A patent/JP2017078082A/ja active Pending
-
2017
- 2017-05-19 HR HRP20170754TT patent/HRP20170754T1/hr unknown
- 2017-06-02 CY CY20171100584T patent/CY1119090T1/el unknown
- 2017-07-27 AU AU2017208313A patent/AU2017208313A1/en not_active Abandoned
-
2018
- 2018-03-15 HK HK18103627.5A patent/HK1244183A1/zh unknown
-
2019
- 2019-08-28 AU AU2019222862A patent/AU2019222862B2/en active Active
- 2019-11-25 HR HRP20192114TT patent/HRP20192114T1/hr unknown
- 2019-12-04 CY CY20191101275T patent/CY1122498T1/el unknown
-
2021
- 2021-02-15 AU AU2021200970A patent/AU2021200970B2/en active Active
- 2021-06-08 AU AU2021203786A patent/AU2021203786B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021203786B2 (en) | Deuterated derivatives of ivacaftor | |
| US20220041557A1 (en) | Deuterated cftr potentiators | |
| AU2012255711A1 (en) | Deuterated derivatives of ivacaftor | |
| JP6146990B2 (ja) | 重水素化されたｃｆｔｒ増強物質 | |
| WO2014078842A1 (en) | Deuterated cftr potentiators | |
| US10759721B2 (en) | Deuterated CFTR potentiators | |
| JP6654223B2 (ja) | 重水素化されたｃｆｔｒ増強物質 | |
| KR102070361B1 (ko) | 중수소화 ｃｆｔｒ 강화제 | |
| JP2017105824A (ja) | 重水素化されたｃｆｔｒ増強物質 |